Lipocine (NASDAQ:LPCN) Announces Quarterly Earnings Results

Lipocine (NASDAQ:LPCN) announced its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, reports.

Lipocine Price Performance

Shares of LPCN stock opened at $4.76 on Friday. The company has a market capitalization of $25.46 million, a PE ratio of -6.26 and a beta of 1.18. The firm’s 50-day moving average is $4.88 and its two-hundred day moving average is $5.62. Lipocine has a 12 month low of $2.35 and a 12 month high of $11.79.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on LPCN. StockNews.com lowered Lipocine from a “buy” rating to a “hold” rating in a research report on Thursday. Alliance Global Partners assumed coverage on Lipocine in a research note on Tuesday, September 24th. They set a “buy” rating and a $10.00 price objective on the stock.

Institutional Trading of Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP acquired a new stake in Lipocine Inc. (NASDAQ:LPCN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.